Part: 12         Session: 145678910111213141516171819202122         Page 931932933934935936937938939940941942943944945946947948949950951952953954955956957958959960961962963964965966967968969970971972973974975976977978979980981982983984985986987988989990991992993994995996997998999 of 999

Well, you've been doing this all your life, persuading. . .

Yes, but I'm not fast enough.

(laughs) Well, you demonstrate a certain degree of impatience.

You have to be impatient.

I'm going to put your purse over here, and there's another question I wanted to ask you which is left over from last time, and that was: you spoke of Schering.

Schering has been making interferon.

But they had given up their attempts with leukocyte and fibroblasts, you said, and were about to concentrate on immune.

Well, I don't know what they're doing about leukocyte now. But they're still making whatever they were making, and they're still interested in it as a possibly widely important, medication.

Now, does Dr. Vilchek of New York University figure in anything?

Yes, he had a lot to do with development of immune interferon.

Is there anything current on him?